DrugBiological
Etaracizumab clinical trials
Also written MEDI-522.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2001
How studies write it
Studies that test it under each name
Name
Brand
Development codes
Studies by the year they started
10 studies that test it; most in 2003 (4)
| Year | Studies |
|---|---|
| 2001 | 3 |
| 2002 | 1 |
| 2003 | 4 |
| 2005 | 1 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
MedImmune LLC (7) · University of Wisconsin, Madison (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Integrin (1) · Dacarbazine (1)
Studies
Open first, then newest update. How each study uses etaracizumab is read from its arms, and is right about nine times in ten.
Testing it · 10
- Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or LymphomaCompletedPhase 1University of Wisconsin, MadisonNCT00049712Written as etaracizumab
- Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT00684996Written as etaracizumab
- Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal CancerCompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT00027729Written as etaracizumab
- Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant MelanomaCompletedPhase 1MedImmune LLCNCT00111696Written as MEDI-522
- Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque PsoriasisCompletedPhase 2MedImmune LLCNCT00192517Written as MEDI-522
- Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid TumorsCompletedPhase 1MedImmune LLCNCT00263783Written as MEDI-522
- Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal CancerCompletedPhase 1/2MedImmune LLCNCT00284817Written as MEDI-522
- MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate CancerCompletedPhase 2MedImmune LLCNCT00072930Written as MEDI-522
- Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic MelanomaCompletedPhase 2MedImmune LLCNCT00066196Written as MEDI--522
- Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to MethotrexateCompletedPhase 2MedImmune LLCNCT00069017Written as MEDI-522
Codes
What other systems call etaracizumab · ClinicalTrials.gg INT004074
- MeSH (NLM) C112567etaracizumabOne source NLM
- UNII (FDA) 41W9MFI160ETARACIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3733647etaracizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1800EtaracizumabOne source FDA
- DrugBank DB12213One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C112567 | etaracizumab | One source NLM |
| UNII (FDA) | 41W9MFI160 | ETARACIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3733647 | etaracizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1800 | Etaracizumab | One source FDA |
| DrugBank | DB12213 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.